Using phospho-SMAD2 as a surrogate for TGFβ activity31, we also observed that the TGFβ neutralizing antibody could inhibit TGFβ activity 50–80% in tumor naïve and tumor bearing tissues (Supplementary Fig. S1 and , , Fig. 3f). Here, TGFB1 is linked to neoplasm.